Gracell Biotechnologies Inc. (GRCL) Tops Q2 EPS by 1c

Gracell Biotechnologies Inc. (NASDAQ: GRCL) reported Q2 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07).

For earnings history and earnings-related data on Gracell Biotechnologies Inc. (GRCL) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Madison Square Garden Sports Corp. (MSGS) Tops Q4 EPS by 62c
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance